Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06376669
Other study ID # J2421
Secondary ID IRB00427823
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date August 2030

Study information

Verified date April 2024
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact Sherif Shaaban
Phone 202-919-2523
Email sshaaba1@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.


Description:

The incidence of kidney cancer diagnosis has been increasing over the last years. Surgical resection represents the mainstay treatment. However, many patients are deemed unfit for surgery due to medical comorbidities or technical limitations. There are non-surgical options including active surveillance, cryotherapy, microwave ablation, radiofrequency and stereotactic radiation therapy (SBRT). SBRT using conventional x-rays has recently been shown to improve outcomes for patients with primary renal cell carcinoma (RCC) in terms of local control and toxicity. However, this treatment was associated with a significant decline in kidney function that necessitates additional intervention including dialysis in some patients. Proton therapy represents an emerging technique with unique properties that allow the bulk of the proton cancer fighting energy to be released at the tumor (Bragg peak) while sparing nearby healthy tissues and organs, particularly the remaining healthy kidney, ipsilateral kidney, bowels, spine and liver. With this technology, both kidneys, the remaining ipsilateral and contralateral, could be spared and thus less damage is expected. This study aims to study the impact of proton based SBRT on the kidney function.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date August 2030
Est. primary completion date June 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. Biopsy proven renal cell carcinoma. 3. No clinical or radiographic evidence of metastatic disease. 4. Not a candidate for surgical treatment or local ablative procedures. 5. Subjects are able to undergo either an MRI or administration of contrast agent for CT. Exclusion Criteria: 1. Prior history of radiation treatment with overlapping fields. 2. Patients with proven metastatic disease. 3. Female subjects who are pregnant or planning to become pregnant during the treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Proton Stereotactic Body Radiation therapy (SBRT)
Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Outcome

Type Measure Description Time frame Safety issue
Primary Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels Change in serum creatine levels from Baseline visit. Baseline and every 3-6 months up to 2 years post treatment
Primary Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values Change in eGFR values from Baseline visit. Baseline and every 3-6 months up to 2 years post treatment
Secondary Number of PROTON-BASED SBRT treatment Adverse Events Adverse events associated with PROTON-BASED SBRT treatment. 24 months post treatment
Secondary Local progression of disease after PROTON-BASED SBRT treatment as assessed by size or appearance of lesions Local progression is defined as an increased size of the primary lesion or appearance of a new lesion in the kidney (within the radiation field). Baseline and every 3-6 months up to 2 years post treatment
Secondary Systemic progression of disease after PROTON-BASED SBRT treatment as assessed by appearance of lesions Systemic progression is defined as appearance of new lesions outside the radiation field (away from the primary tumor). Baseline and every 3-6 months up to 2 years post treatment
Secondary Time to locoregional progression Time to locoregional progression is defined as time from the date of first SBRT PROTON-BASED SBRT fraction to date of locoregional progression, according to RECIST v1.1 criteria. Baseline and every 3-6 months up to 2 years post treatment
Secondary Overall survival Overall survival (OS) is defined as the duration of time from start of treatment to the time of death from any cause. 24 months post treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Not yet recruiting NCT02787915 - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma Phase 1/Phase 2